Skip to content
Companies

BobcatBio

Cancer-specific T cell therapies

Raised to date

$5.3M

of $15M offered across 1 Form D filing

Still open
$9.7M
Investors
11
Last filed
Mar 12, 2025

About

BobcatBio, Inc. is an innovative biotechnology company dedicated to developing advanced cancer therapies that specifically target malignant cells while protecting healthy tissue. Focused on harnessing cutting-edge immunotherapeutic techniques, the company is committed to revolutionizing cancer treatment by creating more effective and less toxic options for patients.

BobcatBio stands out for its approach in utilizing cancer-specific T cell therapies, which represent a novel direction in oncology, aiming for targeted elimination of cancer cells.

Funding

  • EquityFiled Mar 12, 2025Form D
    $5.3M/ $15M

Product

Cancer-Specific T Cell Therapies

Immunotherapy

BobcatBio's flagship product line consists of advanced cancer-specific T cell therapies that are engineered to selectively target cancer cells. These therapies are designed to enhance the immune system's ability to recognize and destroy malignancies while minimizing harm to normal, healthy tissues.

  • Targeted action against cancer cells
  • Reduced toxicity compared to traditional therapies
  • Potential for application across multiple cancer types

Built for

Cancer Patients and Oncology Healthcare Providers

People on file